Cancer Biotherapy & Radiopharmaceuticals

Cancer Biotherapy & Radiopharmaceuticals Published by Mary Ann Liebert Inc. www.liebertpub.com/cbr Peer-reviewed journal covering cutting-edge biotherapy and innovative investigations of methods to improve cancer therapy.
Audience	Researchers, physicians and other practitioners
Frequency	6 issues a year: February, April, June, August, October & December
Editorial Focus	Includes selective delivery of drugs, biologicals, radiopharmaceuticals, or other agents, and advances in delivery instrumentation and technology, with the aim of increasing efficacy of therapy and/or decreasing toxicity or improving convenience of therapy. Topics include: Pre-targeted cancer therapy Clinical trials in cancer research Antibody therapy and imaging Tumor cell vaccines Radioimmunotherapy T-cell therapy Molecular targeted therapy and imaging Drug resistance
Editor(s) in Chief	Gerald L. DeNardo, MD Robert K. Oldham, MD Southeast Missouri Hospital, Oncology-Hematology Clinic, Cape Girardeau
Print Advertising Options	Adverts, Inserts & Supplements
Digital Advertising Options	Banners on website Banners on subscriber Table of Contents email alerts
Further Information	Heleen Vodégel Tel: +44 (0) 1875 825 700 hvodegel@impressmedia.com
Publisher	Cancer Biotherapy & Radiopharmaceuticals is owned and published by Mary Ann Liebert, Inc. Editorial headquarters: 140 Huguenot Street, New Rochelle, New York 10801, USA. Phone: +1 (914) 740-2100. Fax: +1 (914) 740-2101 www.liebertpub.com